demonstrated that detection of serum tau levels increased with disease severity, and that detection was much higher in CM patients, particularly non-survivors, than non-CM patients (Jain et al., 2020; Datta et al., 2021). The gene discussed is MAPT; the disease is cutaneous mastocytosis.